Alcohol-Induced Endocannabinoid Changes Were Not Evidence of Marijuana Exposure

Changes in the endocannabinoid system can arise without administering marijuana. A 2000 review described alcohol-related changes in anandamide and CB1 signaling in preclinical models, making the distinction between endogenous signaling and external cannabis exposure essential.

The review proposed an alcohol mechanism

Hungund and Basavarajappa summarized evidence that chronic ethanol exposure increased anandamide synthesis and was associated with reduced CB1 receptor availability and reduced agonist-stimulated signaling in mouse brain membrane preparations. Anandamide is an endogenous cannabinoid ligand; it is distinct from THC. The review presented an endocannabinoid-system hypothesis for some alcohol effects, including tolerance.

A membrane response is not a THC measurement

The reported signaling assay used mouse brain synaptic plasma membranes. It did not measure THC in human blood, urine or hair. Reduced receptor signaling and the detection of a particular externally consumed drug answer different questions. Accordingly, evidence that ethanol alters a cannabinoid-associated pathway cannot by itself establish that an animal or person received cannabis.

The behavioral evidence had another endpoint

The review also described reduced voluntary alcohol intake after CB1 antagonism in rats and mice. Alcohol consumption, receptor signaling and development of tolerance are separate outcomes; a finding in one does not establish every other link in the proposed pathway. These historical animal observations did not validate a human cannabis-exposure test, an impairment threshold or a treatment recommendation. Their value is mechanistic: they show why the word cannabinoid in a biological pathway should not be read as evidence that marijuana was consumed. The interpretation must retain the administered substance, species, biological preparation and measured endpoint.

Related analysis: a mouse experiment distinguishing basal and stimulated CB1 signaling.

Research cited

Hungund and Basavarajappa (2000). Are anandamide and cannabinoid receptors involved in ethanol tolerance? A review of the evidence. Review abstract.

Spread the love


The National Black Lawyers

top 40 lawyers

civil trial law

Lawyers of Distinction

Loading...

Recent Blog Articles

Later Chemotherapy Cycles Did Not Supply an Analyzed Efficacy Replication

The final trial reported that efficacy results for cycles B and C were not analyzed because of substantial crossover. The first-cycle benefit therefore should not be presented as three separately demonstrated cycles of efficacy. Later treatment histories became mixed The study included different continuation and crossover arrangements across its phases….

Spread the love

Read Article: Later Chemotherapy Cycles Did Not Supply an Analyzed Efficacy Replication

Self-Titration Produced Different Capsule Counts in Active and Placebo Chemotherapy Arms

The chemotherapy study permitted capsule adjustment according to nausea and side effects. Active and placebo participants consequently did not take the same median number of capsules per dose. Capsule content and regimen were specified Each active capsule contained 2.5 milligrams of THC and 2.5 milligrams of CBD. Treatment was scheduled…

Spread the love

Read Article: Self-Titration Produced Different Capsule Counts in Active and Placebo Chemotherapy Arms

Patient-Rated Cannabis Symptoms and Clinician-Graded Adverse Events Gave Different Safety Views

The chemotherapy trial collected both patient-rated cannabinoid-related symptoms and clinician-graded adverse events. Their percentages should not be combined as though they used one severity definition. The assessments used different frameworks Participants completed a structured checklist including sedation, dizziness, anxiety, disorientation, hallucinations and palpitations. Clinicians used the Common Terminology Criteria for…

Spread the love

Read Article: Patient-Rated Cannabis Symptoms and Clinician-Graded Adverse Events Gave Different Safety Views

Speak with an expert today!

Contact the offices of Okorie Okorocha for professional and reliable advice which you can trust.

Call (424) 363-3347 Contact Us